Stephen Connelly - Equillium Chief Scientific Officer, Director
| EQ Stock | USD 1.79 0.07 4.07% |
Director
Mr. Stephen Connelly, Ph.D., is Chief Scientific Officer, Director of the company. He has served as our Chief Scientific Officer since January 2018 and as a member of our board of directors since March 2017. Dr. Connelly is a cofounder of Equillium and served as a consultant from March 2017 until January 2018. Dr. Connelly has served as a principal at BioMed Ventures, an investment firm owned by BioMed Realty, LP, since March 2016. From March 2014 to March 2016, Dr. Connelly served as the Director of Business Development and Therapeutic Alliances at aTyr Pharma, Inc., a publiclyheld biotechnology company. Prior to that, Dr. Connelly was a Senior Scientist at The Scripps Research Institute from March 2012 to March 2014, where he worked on multiple drug discovery projects spanning different therapeutic areas. Dr. Connelly has broad experience in conducting novel and innovative research and has published over 30 original scientific papers and patents since 2018.
| Age | 42 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 2223 Avenida De La Playa, La Jolla, CA, United States, 92037 |
| Phone | 858 240 1200 |
| Web | https://www.equilliumbio.com |
Latest Insider Transactions
Connelly received a B.S. in Medicinal Chemistry and a Ph.D. in Biological Chemistry from the University of Exeter, United Kingdom, and an M.B.A. from the Rady School at University of California, San Diego.Stephen Connelly Latest Insider Activity
Tracking and analyzing the buying and selling activities of Stephen Connelly against Equillium stock is an integral part of due diligence when investing in Equillium. Stephen Connelly insider activity provides valuable insight into whether Equillium is net buyers or sellers over its current business cycle. Note, Equillium insiders must abide by specific rules, including filing SEC forms every time they buy or sell Equillium'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Stephen Connelly 2 days ago Disposition of 8490 shares by Stephen Connelly of Equillium at 7.0842 subject to Rule 16b-3 |
Equillium Management Efficiency
The company has Return on Asset (ROA) of (0.1408) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1408. This is way below average. Likewise, it shows a return on total equity (ROE) of (0.4892) %, which implies that it produced no returns to current stockholders. Equillium's management efficiency ratios could be used to measure how well Equillium manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/25/2024, Return On Tangible Assets is likely to drop to -0.28. In addition to that, Return On Capital Employed is likely to drop to -0.66. At this time, Equillium's Total Current Liabilities is relatively stable compared to the past year. As of 04/25/2024, Liabilities And Stockholders Equity is likely to grow to about 67.5 M, while Non Current Liabilities Total is likely to drop slightly above 364.8 K.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Frank Thomas | Spero Therapeutics | 47 | |
| Timothy Coughlin | aTyr Pharma | 51 | |
| Will Feest | AN2 Therapeutics | N/A | |
| Mark Goldberg | aTyr Pharma | 61 | |
| Lewis Hay | AN2 Therapeutics | 60 | |
| David Southwell | Spero Therapeutics | 56 | |
| Julie Hill | AN2 Therapeutics | 69 | |
| Ervin Wijaya | Bolt Biotherapeutics | 56 | |
| Janto Pangestu | Bolt Biotherapeutics | 59 | |
| Kerry Clark | AN2 Therapeutics | 63 | |
| Jane Gross | aTyr Pharma | N/A | |
| Eliahu Shohet | Bolt Biotherapeutics | 56 | |
| Vikas Goyal | Spero Therapeutics | 37 | |
| Guillermo Gabella | Bolt Biotherapeutics | N/A | |
| JeanFrancois Formela | Spero Therapeutics | 60 | |
| Ramiro Peru | AN2 Therapeutics | 60 | |
| John Short | AN2 Therapeutics | 70 | |
| George Schaefer | AN2 Therapeutics | 70 | |
| Bahija Jallal | AN2 Therapeutics | N/A | |
| Ali Satvat | Coherus BioSciences | 40 | |
| Robert Dixon | AN2 Therapeutics | 60 | |
Management Performance
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.14 |
Equillium Leadership Team
Elected by the shareholders, the Equillium's board of directors comprises two types of representatives: Equillium inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Equillium. The board's role is to monitor Equillium's management team and ensure that shareholders' interests are well served. Equillium's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Equillium's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Fisher, Independent Director | ||
| Jason Keyes, Chief Officer | ||
| Penny Tom, Principal Officer | ||
| Anthony Tjan, Independent Director | ||
| Daniel Bradbury, Chairman of the Board, CEO | ||
| Joel Rothman, Chief Officer | ||
| Krishna Polu, Chief Medical Officer | ||
| Marc Lavine, Independent Director | ||
| Charles McDermott, Independent Director | ||
| Bruce Steel, President Chief Business Officer and Director | ||
| PMP MBA, Senior COO | ||
| Matthew Ritter, Senior Development | ||
| Maple MD, Chief Officer | ||
| Krishna MD, Consultant | ||
| Geoffrey Rotstein, President CEO, Director | ||
| Bruce CFA, President, CoFounder | ||
| Bala Manian, Independent Director | ||
| Michael Moore, Vice Communications | ||
| Dilshan Kathriarachchi, CTO | ||
| Stephen Connelly, Chief Scientific Officer, Director | ||
| Peter Kanniah, CFO, Secretary | ||
| Martha Demski, Independent Director | ||
| Mark Pruzanski, Independent Director | ||
| Vernon Lobo, Independent Chairman of the Board |
Equillium Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Equillium a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.37) % | ||||
| Operating Margin | (0.35) % | ||||
| Current Valuation | 20.6 M | ||||
| Shares Outstanding | 35.25 M | ||||
| Shares Owned By Insiders | 36.42 % | ||||
| Shares Owned By Institutions | 21.76 % | ||||
| Number Of Shares Shorted | 394.47 K | ||||
| Price To Earning | (6.70) X |
Pair Trading with Equillium
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Equillium position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Equillium will appreciate offsetting losses from the drop in the long position's value.Moving together with Equillium Stock
| 0.65 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
Moving against Equillium Stock
| 0.46 | GILD | Gilead Sciences Earnings Call Today | PairCorr |
The ability to find closely correlated positions to Equillium could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Equillium when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Equillium - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Equillium to buy it.
The correlation of Equillium is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Equillium moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Equillium moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Equillium can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Equillium. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. To learn how to invest in Equillium Stock, please use our How to Invest in Equillium guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Complementary Tools for Equillium Stock analysis
When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |
Is Equillium's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Equillium. If investors know Equillium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Equillium listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.38) | Revenue Per Share 1.039 | Quarterly Revenue Growth (0.42) | Return On Assets (0.14) | Return On Equity (0.49) |
The market value of Equillium is measured differently than its book value, which is the value of Equillium that is recorded on the company's balance sheet. Investors also form their own opinion of Equillium's value that differs from its market value or its book value, called intrinsic value, which is Equillium's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Equillium's market value can be influenced by many factors that don't directly affect Equillium's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Equillium's value and its price as these two are different measures arrived at by different means. Investors typically determine if Equillium is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Equillium's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.